Order Article Reprints

Shani Shrem N, Beltran-Bless A-A, Ghosh S, Tajzler C, Wood LA, Kollmannsberger C, Basappa NS, Graham J, Fallah-Rad N, Heng DYC, et al. Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients. Cancers. 2025; 17(3):522. https://doi.org/10.3390/cancers17030522

Shani Shrem, Noa, Ana-Alicia Beltran-Bless, Sunita Ghosh, Camilla Tajzler, Lori A. Wood, Christian Kollmannsberger, Naveen S. Basappa, Jeffrey Graham, Nazanin Fallah-Rad, Daniel Y.C. Heng, and et al. 2025. "Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients" Cancers 17, no. 3: 522. https://doi.org/10.3390/cancers17030522

Shani Shrem, N., Beltran-Bless, A.-A., Ghosh, S., Tajzler, C., Wood, L. A., Kollmannsberger, C., Basappa, N. S., Graham, J., Fallah-Rad, N., Heng, D. Y. C., Soulières, D., Lalani, A.-K. A., Breau, R. H., Finelli, A., Tanguay, S., Bhindi, B., Bjarnason, G., Pouliot, F., & Canil, C. (2025). Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients. Cancers, 17(3), 522. https://doi.org/10.3390/cancers17030522